Novartis has agreed to pay up to $1.7 billion to license an experimental Alzheimer’s therapy from China-based SciNeuro, a megadeal that signals how aggressively big pharma is now chasing ...
The right approaches are demonstrating that it is possible to breach the defensively designed blood-brain barrier despite its ...
Series A financing will be used to advance Aerska's brain shuttle technology to improve the delivery of RNA interference therapeutics for neurological diseases Financing was co-led by EQT Life ...
ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company specializing in treatments for rare and muscular diseases, ...
Stuart Milstein appointed Chief Platform Officer, bringing decades of experience in oligonucleotide drug development to underpin Aerska’s platform R&D Lisa Taylor Ash joins Board of Directors, ...
The blood-brain border has long stymied drug development for neurodegenerative diseases. In recent years, Denali, Roche, and others have designed molecular brain shuttles that ferry investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results